Franklin Genomic Advancements Etf Profile
| HELX Etf | USD 29.24 0.44 1.53% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Franklin Genomic is trading at 29.24 as of the 21st of November 2024; that is 1.53 percent increase since the beginning of the trading day. The etf's open price was 28.8. Franklin Genomic has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Franklin Genomic Advancements are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Under normal market conditions, the fund invests at least 80 percent of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. Franklin Genomic is traded on BATS Exchange in the United States. More on Franklin Genomic Advancements
Moving together with Franklin Etf
| 0.94 | XLV | Health Care Select | PairCorr |
| 0.96 | VHT | Vanguard Health Care | PairCorr |
| 0.88 | IBB | iShares Biotechnology ETF | PairCorr |
| 0.67 | XBI | SPDR SP Biotech | PairCorr |
| 0.94 | IXJ | iShares Global Healthcare | PairCorr |
Moving against Franklin Etf
Franklin Etf Highlights
| Thematic Ideas | (View all Themes) |
| Old Name | GlobalBlock Digital Asset Trading Limited |
| Business Concentration | Strategy ETFs, Theme ETFs, Health, Franklin Templeton Investments (View all Sectors) |
| Issuer | Franklin Templeton Investments |
| Inception Date | 2020-02-25 |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 10.23 Million |
| Asset Type | Equity |
| Category | Strategy |
| Focus | Theme |
| Market Concentration | Blended Development |
| Region | Global |
| Administrator | Franklin Templeton Services, LLC |
| Advisor | Franklin Advisers, Inc. |
| Custodian | State Street Bank and Trust Company |
| Distributor | Franklin Templeton Distributors, Inc. |
| Portfolio Manager | Matthew J.Moberg, Joyce Lin |
| Transfer Agent | State Street Bank and Trust Company |
| Fiscal Year End | 31-Mar |
| Exchange | Cboe BZX Exchange, Inc. |
| Number of Constituents | 66.0 |
| Market Maker | Citadel |
| Total Expense | 0.5 |
| Management Fee | 0.5 |
| Country Name | USA |
| Returns Y T D | (5.47) |
| Name | Franklin Genomic Advancements ETF |
| Currency Code | USD |
| Open Figi | BBG00RRGPCJ1 |
| In Threey Volatility | 22.91 |
| 1y Volatility | 20.7 |
| 200 Day M A | 31.8847 |
| 50 Day M A | 31.5801 |
| Code | HELX |
| Updated At | 21st of November 2024 |
| Currency Name | US Dollar |
| In Threey Sharp Ratio | (0.89) |
| Type | ETF |
Franklin Genomic Advancements [HELX] is traded in USA and was established 2020-02-25. The fund is listed under Health category and is part of Franklin Templeton Investments family. The entity is thematically classified as Strategy ETFs. Franklin Genomic Adv currently have 10.39 M in assets under management (AUM). , while the total return for the last 3 years was -17.1%.
Check Franklin Genomic Probability Of Bankruptcy
Geographic Allocation (%)
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Franklin Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Franklin Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as Franklin Genomic Advancements Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Franklin Genomic Adv Currency Exposure
Franklin Genomic Advancements holds assets that are exposed to currency risk. As an investor, you have to ensure that the increase in value or dividend from foreign constituents of Franklin Genomic will not be offset by an unfavorable exchange rate and will not cancel out the return on assets from different countries. In other words, assess how much of your investment depends on the development of foreign currencies before you invest in Franklin Genomic Advancements.
Top Franklin Genomic Advancements Etf Constituents
| MEDP | Medpace Holdings | Stock | Health Care | |
| VRTX | Vertex Pharmaceuticals | Stock | Health Care | |
| VEEV | Veeva Systems Class | Stock | Health Care | |
| TXG | 10X Genomics | Stock | Health Care | |
| TMO | Thermo Fisher Scientific | Stock | Health Care | |
| TDOC | Teladoc | Stock | Health Care | |
| RGEN | Repligen | Stock | Health Care | |
| REGN | Regeneron Pharmaceuticals | Stock | Health Care |
Franklin Genomic Adv Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Franklin Genomic. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | (0.20) |
Franklin Genomic Against Markets
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Franklin Genomic Advancements. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.